KDR and intrahepatic cholangiocarcinoma: Studies have well-characterized the role of CAFs in ICC tumors, and Yamanaka et al. demonstrated that administration of nintedanib (tyrosine-kinase inhibitor targeting VEGFR, PDGFR, and FGFR) could suppress the protumoral effects of CAFs derived from ICC tissues both in vitro and in vivo [141].